ReviewTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2021
Laboratory Monitoring of Mother, Fetus, and Newborn in Hemolytic Disease of Fetus and Newborn.
Review in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- The Utility of a Critical Antibody Titer in Anti-K Alloimmunized Pregnancies: A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy.Transfusion medicine reviews · 2025Pooled it
- Hemolytic disease of the fetus and newborn: systematic literature review of the antenatal landscape.BMC pregnancy and childbirth · 2023Pooled it
- Global, Regional and National Burden of Hemolytic Disease and Other Neonatal Jaundice, 1980/90-2021, and Projections to 2050: A Global Burden of Disease Study 2021.Health science reports · 2026Article
- A Retrospective Study on Neonatal Jaundice: Early Risk Stratification Value of DAT-FAT Serological Profiles Confirmed by AET.The Kaohsiung journal of medical sciences · 2026Article
- Clinical characteristics and outcomes of pregnancies at-risk of hemolytic disease of the fetus and newborn in Sweden, Finland, and Denmark: a population-based register study.AJOG global reports · 2025Article
- Neonatal Hemolytic Jaundice: Causes, Diagnostic Approach, and Management.Children (Basel, Switzerland) · 2025Review
- Neonatal JkBMC pediatrics · 2025Review
- Noninvasive fetal blood group antigen genotyping.Blood transfusion = Trasfusione del sangue · 2025Review
- [Colombian consensus for the diagnosis, prevention, and management of Rhesus disease].Revista colombiana de obstetricia y ginecologia · 2024Article
- DAHEAN: A Danish nationwide study ensuring quality assurance through real-world data for suspected hereditary anemia patients.Orphanet journal of rare diseases · 2024Article
- Evaluation of an automated platform for non-invasive single-exon fetal RHD genotyping early in pregnancy.Blood transfusion = Trasfusione del sangue · 2023Article
- Hemolytic disease of the fetus and newborn: rapid review of postnatal care and outcomes.BMC pregnancy and childbirth · 2023Review
- Clinical value of combined predictors of RET%, γ-GT, LDH in the ABO neonatal hemolytic disease.Frontiers in pediatrics · 2023Article
- Non-Invasive Fetal K Status Prediction: 7 Years of Experience.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLaboratory monitoring of mother, fetus, and newborn in hemolytic disease of fetus and newborn (HDFN) aims to guide clinicians and the immunized women to focus on the most serious problems of alloimmunization and thus minimize the consequences of HDFN in general and of anti-D in particular. Here, we present the current approach of laboratory screening and testing for prevention and monitoring of HDFN at the Copenhagen University Hospital in Denmark. SUMMARY: All pregnant women are typed and screened in the 1st trimester. This serves to identify the RhD-negative pregnant women who at gestational age (GA) of 25 weeks are offered a second screen test and a non-invasive fetal RhD prediction. At GA 29 weeks, and again after delivery, non-immunized RhD-negative women carrying an RhD-positive fetus are offered Rh immunoglobulin. If the 1st trimester screen reveals an alloantibody, antenatal investigation is initiated. This also includes RhD-positive women with alloantibodies. Specificity and titer are determined, the fetal phenotype is predicted by non-invasive genotyping based on cell-free DNA (RhD, K, Rhc, RhC, RhE, ABO), and serial monitoring of titer commences. Based on titers and specificity, monitoring with serial peak systolic velocity measurements in the fetal middle cerebral artery to detect anemia will take place. Intrauterine transfusion is given when fetal anemia is suspected. Monitoring of the newborn by titer and survival of fetal red blood cells by flow cytometry will help predict the length of the recovery of the newborn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.